Note to users. If you're seeing this message, it means that your browser cannot find this page's style/presentation instructions -- or possibly that you are using a browser that does not support current Web standards. Find out more about why this message is appearing, and what you can do to make your experience of our site the best it can be.

Science 13 November 1998:
Vol. 282. no. 5392, pp. 1332 - 1334
DOI: 10.1126/science.282.5392.1332
Prev | Table of Contents | Next

Reports

Reovirus Therapy of Tumors with Activated Ras Pathway

Matthew C. Coffey, James E. Strong, Peter A. Forsyth, Patrick W. K. Lee *

Human reovirus requires an activated Ras signaling pathway for infection of cultured cells. To investigate whether this property can be exploited for cancer therapy, severe combined immune deficient mice bearing tumors established from v-erbB-transformed murine NIH 3T3 cells or human U87 glioblastoma cells were treated with the virus. A single intratumoral injection of virus resulted in regression of tumors in 65 to 80 percent of the mice. Treatment of immune-competent C3H mice bearing tumors established from ras-transformed C3H-10T1/2 cells also resulted in tumor regression, although a series of injections were required. These results suggest that, with further work, reovirus may have applicability in the treatment of cancer.

M. C. Coffey, J. E. Strong, P. W. K. Lee, Cancer Biology Research Group and Department of Microbiology and Infectious Diseases, University of Calgary Health Science Centre, Calgary, Alberta, T2N 4N1, Canada. P. A. Forsyth, Cancer Biology Research Group and Department of Oncology, University of Calgary Health Science Centre, Calgary, Alberta, T2N 4N1, Canada.
*   To whom correspondence should be addressed. E- mail: plee{at}acs.ucalgary.ca

Read the Full Text


THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES:
Reciprocal Human Dendritic Cell-Natural Killer Cell Interactions Induce Antitumor Activity Following Tumor Cell Infection by Oncolytic Reovirus.
R. J. Prestwich, F. Errington, L. P. Steele, E. J. Ilett, R. S. M. Morgan, K. J. Harrington, H. S. Pandha, P. J. Selby, R. G. Vile, and A. A. Melcher (2009)
J. Immunol. 183, 4312-4321
   Abstract »    Full Text »    PDF »
Synergistic Effects of Oncolytic Reovirus and Cisplatin Chemotherapy in Murine Malignant Melanoma.
H. S. Pandha, L. Heinemann, G. R. Simpson, A. Melcher, R. Prestwich, F. Errington, M. Coffey, K. J. Harrington, and R. Morgan (2009)
Clin. Cancer Res. 15, 6158-6166
   Abstract »    Full Text »    PDF »
Coronavirus Genetically Redirected to the Epidermal Growth Factor Receptor Exhibits Effective Antitumor Activity against a Malignant Glioblastoma.
M. H. Verheije, M. L. M. Lamfers, T. Wurdinger, G. C. M. Grinwis, W. R. Gerritsen, V. W. van Beusechem, and P. J. M. Rottier (2009)
J. Virol. 83, 7507-7516
   Abstract »    Full Text »    PDF »
Immune-Mediated Antitumor Activity of Reovirus Is Required for Therapy and Is Independent of Direct Viral Oncolysis and Replication.
R. J. Prestwich, E. J. Ilett, F. Errington, R. M. Diaz, L. P. Steele, T. Kottke, J. Thompson, F. Galivo, K. J. Harrington, H. S. Pandha, et al. (2009)
Clin. Cancer Res. 15, 4374-4381
   Abstract »    Full Text »    PDF »
Efficacy of Systemically Administered Oncolytic Vaccinia Virotherapy for Malignant Gliomas Is Enhanced by Combination Therapy with Rapamycin or Cyclophosphamide.
X. Q. Lun, J.-H. Jang, N. Tang, H. Deng, R. Head, J. C. Bell, D. F. Stojdl, C. L. Nutt, D. L. Senger, P. A. Forsyth, et al. (2009)
Clin. Cancer Res. 15, 2777-2788
   Abstract »    Full Text »    PDF »
A Multiscale Mathematical Model for Oncolytic Virotherapy.
L. R. Paiva, C. Binny, S. C. Ferreira Jr., and M. L. Martins (2009)
Cancer Res. 69, 1205-1211
   Abstract »    Full Text »    PDF »
Improved Systemic Delivery of Oncolytic Reovirus to Established Tumors Using Preconditioning with Cyclophosphamide-Mediated Treg Modulation and Interleukin-2.
T. Kottke, J. Thompson, R. M. Diaz, J. Pulido, C. Willmon, M. Coffey, P. Selby, A. Melcher, K. Harrington, and R. G. Vile (2009)
Clin. Cancer Res. 15, 561-569
   Abstract »    Full Text »    PDF »
Ras Signaling Influences Permissiveness of Malignant Peripheral Nerve Sheath Tumor Cells to Oncolytic Herpes.
F. Farassati, W. Pan, F. Yamoutpour, S. Henke, M. Piedra, S. Frahm, S. Al-Tawil, W. I. Mangrum, L. F. Parada, S. D. Rabkin, et al. (2008)
Am. J. Pathol. 173, 1861-1872
   Abstract »    Full Text »    PDF »
A Phase I Study of Intravenous Oncolytic Reovirus Type 3 Dearing in Patients with Advanced Cancer.
L. Vidal, H. S. Pandha, T. A. Yap, C. L. White, K. Twigger, R. G. Vile, A. Melcher, M. Coffey, K. J. Harrington, and J. S. DeBono (2008)
Clin. Cancer Res. 14, 7127-7137
   Abstract »    Full Text »    PDF »
Reovirus Activates Human Dendritic Cells to Promote Innate Antitumor Immunity.
F. Errington, L. Steele, R. Prestwich, K. J. Harrington, H. S. Pandha, L. Vidal, J. de Bono, P. Selby, M. Coffey, R. Vile, et al. (2008)
J. Immunol. 180, 6018-6026
   Abstract »    Full Text »    PDF »
Enhanced In vitro and In vivo Cytotoxicity of Combined Reovirus and Radiotherapy.
K. Twigger, L. Vidal, C. L. White, J. S. De Bono, S. Bhide, M. Coffey, B. Thompson, R. G. Vile, L. Heinemann, H. S. Pandha, et al. (2008)
Clin. Cancer Res. 14, 912-923
   Abstract »    Full Text »    PDF »
Cyclophosphamide Facilitates Antitumor Efficacy against Subcutaneous Tumors following Intravenous Delivery of Reovirus.
J. Qiao, H. Wang, T. Kottke, C. White, K. Twigger, R. M. Diaz, J. Thompson, P. Selby, J. de Bono, A. Melcher, et al. (2008)
Clin. Cancer Res. 14, 259-269
   Abstract »    Full Text »    PDF »
Positron Emission Tomography of Herpes Simplex Virus 1 Oncolysis.
D. Kuruppu, A.-L. Brownell, A. Zhu, M. Yu, X. Wang, Y. Kulu, B. C. Fuchs, H. Kawasaki, and K. K. Tanabe (2007)
Cancer Res. 67, 3295-3300
   Abstract »    Full Text »    PDF »
Oncolytic Treatment and Cure of Neuroblastoma by a Novel Attenuated Poliovirus in a Novel Poliovirus-Susceptible Animal Model.
H. Toyoda, J. Yin, S. Mueller, E. Wimmer, and J. Cello (2007)
Cancer Res. 67, 2857-2864
   Abstract »    Full Text »    PDF »
Oncolytic Virotherapy Synergism with Signaling Inhibitors: Rapamycin Increases Myxoma Virus Tropism for Human Tumor Cells.
M. M. Stanford, J. W. Barrett, S. H. Nazarian, S. Werden, and G. McFadden (2007)
J. Virol. 81, 1251-1260
   Abstract »    Full Text »    PDF »
Effects of Intravenously Administered Recombinant Vesicular Stomatitis Virus (VSV{Delta}M51) on Multifocal and Invasive Gliomas..
X. Lun, D. L. Senger, T. Alain, A. Oprea, K. Parato, D. Stojdl, B. Lichty, A. Power, R. N. Johnston, M. Hamilton, et al. (2006)
J Natl Cancer Inst 98, 1546-1557
   Abstract »    Full Text »    PDF »
Oncolytic efficacy and enhanced safety of measles virus activated by tumor-secreted matrix metalloproteinases..
C. Springfeld, V. von Messling, M. Frenzke, G. Ungerechts, C. J. Buchholz, and R. Cattaneo (2006)
Cancer Res. 66, 7694-7700
   Abstract »    Full Text »    PDF »
KRASD13 Promotes Apoptosis of Human Colorectal Tumor Cells by ReovirusT3D and Oxaliplatin but not by Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand..
N. Smakman, D. J.M. van den Wollenberg, S. G. Elias, T. Sasazuki, S. Shirasawa, R. C. Hoeben, I. H.M. Borel Rinkes, and O. Kranenburg (2006)
Cancer Res. 66, 5403-5408
   Abstract »    Full Text »    PDF »
Combination of a Fusogenic Glycoprotein, Prodrug Activation, and Oncolytic Herpes Simplex Virus for Enhanced Local Tumor Control..
G. R. Simpson, Z. Han, B. Liu, Y. Wang, G. Campbell, and R. S. Coffin (2006)
Cancer Res. 66, 4835-4842
   Abstract »    Full Text »    PDF »
Glioma Virotherapy: Effects of Innate Immune Suppression and Increased Viral Replication Capacity.
A. Friedman, J. P. Tian, G. Fulci, E. A. Chiocca, and J. Wang (2006)
Cancer Res. 66, 2314-2319
   Abstract »    Full Text »    PDF »
Targeted Therapy for Glioblastoma Multiforme Neoplastic Meningitis with Intrathecal Delivery of an Oncolytic Recombinant Poliovirus.
H. Ochiai, S. A. Campbell, G. E. Archer, T. A. Chewning, E. Dragunsky, A. Ivanov, M. Gromeier, and J. H. Sampson (2006)
Clin. Cancer Res. 12, 1349-1354
   Abstract »    Full Text »    PDF »
Effect of Chemotherapy-Induced DNA Repair on Oncolytic Herpes Simplex Viral Replication.
M. Aghi, S. Rabkin, and R. L. Martuza (2006)
J Natl Cancer Inst 98, 38-50
   Abstract »    Full Text »    PDF »
Sensitization to Apoptosis Underlies KrasD12-Dependent Oncolysis of Murine C26 Colorectal Carcinoma Cells by Reovirus T3D.
N. Smakman, D. J. M. van den Wollenberg, I. H. M. B. Rinkes, R. C. Hoeben, and O. Kranenburg (2005)
J. Virol. 79, 14981-14985
   Abstract »    Full Text »    PDF »
Myxoma Virus Is a Novel Oncolytic Virus with Significant Antitumor Activity against Experimental Human Gliomas.
X. Lun, W. Yang, T. Alain, Z.-Q. Shi, H. Muzik, J. W. Barrett, G. McFadden, J. Bell, M. G. Hamilton, D. L. Senger, et al. (2005)
Cancer Res. 65, 9982-9990
   Abstract »    Full Text »    PDF »
Regulation of polymeric immunoglobulin receptor expression by reovirus.
K. Pal, C. S. Kaetzel, K. Brundage, C. A. Cunningham, and C. F. Cuff (2005)
J. Gen. Virol. 86, 2347-2357
   Abstract »    Full Text »    PDF »
Correlation between interferon sensitivity of reovirus isolates and ability to discriminate between normal and Ras-transformed cells.
P. Rudd and G. Lemay (2005)
J. Gen. Virol. 86, 1489-1497
   Abstract »    Full Text »    PDF »
Construction of a Minimal HIV-1 Variant that Selectively Replicates in Leukemic Derived T-Cell Lines: Towards a New Virotherapy Approach.
R. E. Jeeninga, B. Jan, B. van der Linden, H. van den Berg, and B. Berkhout (2005)
Cancer Res. 65, 3347-3355
   Abstract »    Full Text »    PDF »
In vitro Canine Distemper Virus Infection of Canine Lymphoid Cells: A Prelude to Oncolytic Therapy for Lymphoma.
S. E. Suter, M. B. Chein, V. von Messling, B. Yip, R. Cattaneo, W. Vernau, B. R. Madewell, and C. A. London (2005)
Clin. Cancer Res. 11, 1579-1587
   Abstract »    Full Text »    PDF »
Efficacy and Safety Evaluation of Human Reovirus Type 3 in Immunocompetent Animals: Racine and Nonhuman Primates.
W. Q. Yang, X. Lun, C. A. Palmer, M. E. Wilcox, H. Muzik, Z. Q. Shi, R. Dyck, M. Coffey, B. Thompson, M. Hamilton, et al. (2004)
Clin. Cancer Res. 10, 8561-8576
   Abstract »    Full Text »    PDF »
Reovirus oncolysis: The Ras/RalGEF/p38 pathway dictates host cell permissiveness to reovirus infection.
K. L. Norman, K. Hirasawa, A.-D. Yang, M. A. Shields, and P. W. K. Lee (2004)
PNAS 101, 11099-11104
   Abstract »    Full Text »    PDF »
High CD46 Receptor Density Determines Preferential Killing of Tumor Cells by Oncolytic Measles Virus.
B. D. Anderson, T. Nakamura, S. J. Russell, and K.-W. Peng (2004)
Cancer Res. 64, 4919-4926
   Abstract »    Full Text »    PDF »
Treatment of Intracerebral Neoplasia and Neoplastic Meningitis with Regional Delivery of Oncolytic Recombinant Poliovirus.
H. Ochiai, S. A. Moore, G. E. Archer, T. Okamura, T. A. Chewning, J. R. Marks, J. H. Sampson, and M. Gromeier (2004)
Clin. Cancer Res. 10, 4831-4838
   Abstract »    Full Text »    PDF »
Poliovirus receptor CD155-targeted oncolysis of glioma.
M. K. Merrill, G. Bernhardt, J. H. Sampson, C. J. Wikstrand, D. D. Bigner, and M. Gromeier (2004)
Neuro-oncol 6, 208-217
   Abstract »    PDF »
A Cox-2 Promoter-Based Replication-Selective Adenoviral Vector to Target the Cox-2-Expressing Human Bladder Cancer Cells.
T. Shirakawa, K. Hamada, Z. Zhang, H. Okada, M. Tagawa, S. Kamidono, M. Kawabata, and A. Gotoh (2004)
Clin. Cancer Res. 10, 4342-4348
   Abstract »    Full Text »    PDF »
Syncytia Induction Enhances the Oncolytic Potential of Vesicular Stomatitis Virus in Virotherapy for Cancer.
O. Ebert, K. Shinozaki, C. Kournioti, M.-S. Park, A. Garcia-Sastre, and S. L. C. Woo (2004)
Cancer Res. 64, 3265-3270
   Abstract »    Full Text »    PDF »
Endocrine Aspects of Cancer Gene Therapy.
L. Barzon, M. Boscaro, and G. Palu (2004)
Endocr. Rev. 25, 1-44
   Abstract »    Full Text »    PDF »
Development of Recombinant Vesicular Stomatitis Viruses That Exploit Defects in Host Defense To Augment Specific Oncolytic Activity.
M. Obuchi, M. Fernandez, and G. N. Barber (2003)
J. Virol. 77, 8843-8856
   Abstract »    Full Text »    PDF »
Melanoma Differentiation-associated 7 (Interleukin 24) Inhibits Growth and Enhances Radiosensitivity of Glioma Cells in Vitro and in Vivo.
A. Yacoub, C. Mitchell, A. Lister, I. V. Lebedeva, D. Sarkar, Z.-Z. Su, C. Sigmon, R. McKinstry, V. Ramakrishnan, L. Qiao, et al. (2003)
Clin. Cancer Res. 9, 3272-3281
   Abstract »    Full Text »    PDF »
Oncolytic Vesicular Stomatitis Virus for Treatment of Orthotopic Hepatocellular Carcinoma in Immune-competent Rats.
O. Ebert, K. Shinozaki, T.-G. Huang, M. J. Savontaus, A. Garcia-Sastre, and S. L. C. Woo (2003)
Cancer Res. 63, 3605-3611
   Abstract »    Full Text »    PDF »
Reovirus oncolysis as a novel purging strategy for autologous stem cell transplantation.
C. M. Thirukkumaran, J. M. Luider, D. A. Stewart, T. Cheng, S. M. Lupichuk, M. J. Nodwell, J. A. Russell, I. A. Auer, and D. G. Morris (2003)
Blood 102, 377-387
   Abstract »    Full Text »    PDF »
Reovirus Prolongs Survival and Reduces the Frequency of Spinal and Leptomeningeal Metastases from Medulloblastoma.
W. Q. Yang, D. Senger, H. Muzik, Z. Q. Shi, D. Johnson, P. M. A. Brasher, N. B. Rewcastle, M. Hamilton, J. Rutka, J. Wolff, et al. (2003)
Cancer Res. 63, 3162-3172
   Abstract »    Full Text »    PDF »
Validation and Analysis of a Mathematical Model of a Replication-competent Oncolytic Virus for Cancer Treatment: Implications for Virus Design and Delivery.
L. M. Wein, J. T. Wu, and D. H. Kirn (2003)
Cancer Res. 63, 1317-1324
   Abstract »    Full Text »    PDF »
Oncolytic Viral Therapy for Human Pancreatic Cancer Cells by Reovirus.
T. Etoh, Y. Himeno, T. Matsumoto, M. Aramaki, K. Kawano, A. Nishizono, and S. Kitano (2003)
Clin. Cancer Res. 9, 1218-1223
   Abstract »    Full Text »    PDF »
Systemic Reovirus Therapy of Metastatic Cancer in Immune-competent Mice.
K. Hirasawa, S. G. Nishikawa, K. L. Norman, M. C. Coffey, B. G. Thompson, C.-S. Yoon, D. M. Waisman, and P. W. K. Lee (2003)
Cancer Res. 63, 348-353
   Abstract »    Full Text »    PDF »
Gene therapy for colorectal cancer.
D. H Palmer, M.-J. Chen, and D. J Kerr (2002)
Br. Med. Bull. 64, 201-225
   Abstract »    Full Text »    PDF »
Reovirus therapy of lymphoid malignancies.
T. Alain, K. Hirasawa, K. J. Pon, S. G. Nishikawa, S. J. Urbanski, Y. Auer, J. Luider, A. Martin, R. N. Johnston, A. Janowska-Wieczorek, et al. (2002)
Blood 100, 4146-4153
   Abstract »    Full Text »    PDF »
Hepatic Arterial Infusion of a Replication-selective Oncolytic Adenovirus (dl1520): Phase II Viral, Immunologic, and Clinical Endpoints.
T. Reid, E. Galanis, J. Abbruzzese, D. Sze, L. M. Wein, J. Andrews, B. Randlev, C. Heise, M. Uprichard, M. Hatfield, et al. (2002)
Cancer Res. 62, 6070-6079
   Abstract »    Full Text »    PDF »
Addition of Exogenous Protease Facilitates Reovirus Infection in Many Restrictive Cells.
J. W. Golden, J. Linke, S. Schmechel, K. Thoemke, and L. A. Schiff (2002)
J. Virol. 76, 7430-7443
   Abstract »    Full Text »    PDF »
Viral Oncolysis.
J. T. Mullen and K. K. Tanabe (2002)
Oncologist 7, 106-119
   Abstract »    Full Text »    PDF »
Oncolytic Reovirus against Ovarian and Colon Cancer.
K. Hirasawa, S. G. Nishikawa, K. L. Norman, T. Alain, A. Kossakowska, and P. W. K. Lee (2002)
Cancer Res. 62, 1696-1701
   Abstract »    Full Text »    PDF »
Treatment of Malignant Gliomas with a Replicating Adenoviral Vector Expressing Herpes Simplex Virus-Thymidine Kinase.
D. Nanda, R. Vogels, M. Havenga, C. J. Avezaat, A. Bout, and P. S. Smitt (2001)
Cancer Res. 61, 8743-8750
   Abstract »    Full Text »    PDF »
A Genetically Engineered Influenza A Virus with ras-Dependent Oncolytic Properties.
M. Bergmann, I. Romirer, M. Sachet, R. Fleischhacker, A. Garcia-Sastre, P. Palese, K. Wolff, H. Pehamberger, R. Jakesz, and T. Muster (2001)
Cancer Res. 61, 8188-8193
   Abstract »    Full Text »    PDF »
Systemic therapy of myeloma xenografts by an attenuated measles virus.
K.-W. Peng, G. J. Ahmann, L. Pham, P. R. Greipp, R. Cattaneo, and S. J. Russell (2001)
Blood 98, 2002-2007
   Abstract »    Full Text »    PDF »
Multimodality Therapy with a Replication-conditional Herpes Simplex Virus 1 Mutant that Expresses Yeast Cytosine Deaminase for Intratumoral Conversion of 5-Fluorocytosine to 5-Fluorouracil.
H. Nakamura, J. T. Mullen, S. Chandrasekhar, T. M. Pawlik, S. S. Yoon, and K. K. Tanabe (2001)
Cancer Res. 61, 5447-5452
   Abstract »    Full Text »    PDF »
Viruses as Therapeutic Agents Against Malignant Disease of the Central Nervous System.
M. Gromeier (2001)
J Natl Cancer Inst 93, 889-890
   Full Text »    PDF »
Reovirus as an Oncolytic Agent Against Experimental Human Malignant Gliomas.
M. E. Wilcox, W. Yang, D. Senger, N. B. Rewcastle, D. G. Morris, P. M. A. Brasher, Z. Q. Shi, R. N. Johnston, S. Nishikawa, P. W. K. Lee, et al. (2001)
J Natl Cancer Inst 93, 903-912
   Abstract »    Full Text »    PDF »
Live attenuated measles virus induces regression of human lymphoma xenografts in immunodeficient mice.
D. Grote, S. J. Russell, T. I. Cornu, R. Cattaneo, R. Vile, G. A. Poland, and A. K. Fielding (2001)
Blood 97, 3746-3754
   Abstract »    Full Text »    PDF »
Potential of gene therapy for brain tumors.
P. Y.P. Lam and X. O. Breakefield (2001)
Hum. Mol. Genet. 10, 777-787
   Abstract »    Full Text »    PDF »
Oncolytic Activity of Vesicular Stomatitis Virus Is Effective against Tumors Exhibiting Aberrant p53, Ras, or Myc Function and Involves the Induction of Apoptosis.
S. Balachandran, M. Porosnicu, and G. N. Barber (2001)
J. Virol. 75, 3474-3479
   Abstract »    Full Text »
Grb2 and Shc Adapter Proteins Play Distinct Roles in Neu (ErbB-2)-Induced Mammary Tumorigenesis: Implications for Human Breast Cancer.
D. Dankort, B. Maslikowski, N. Warner, N. Kanno, H. Kim, Z. Wang, M. F. Moran, R. G. Oshima, R. D. Cardiff, and W. J. Muller (2001)
Mol. Cell. Biol. 21, 1540-1551
   Abstract »    Full Text »
Interferon resistance of cutaneous T-cell lymphoma-derived clonal T-helper 2 cells allows selective viral replication.
R. Dummer, U. Dobbeling, R. Geertsen, J. Willers, G. Burg, and J. Pavlovic (2001)
Blood 97, 523-527
   Abstract »    Full Text »    PDF »
Recombinant Measles Viruses Efficiently Entering Cells through Targeted Receptors.
U. Schneider, F. Bullough, S. Vongpunsawad, S. J. Russell, and R. Cattaneo (2000)
J. Virol. 74, 9928-9936
   Abstract »    Full Text »
Influenza Virus NS1 Protein Counteracts PKR-Mediated Inhibition of Replication.
M. Bergmann, A. Garcia-Sastre, E. Carnero, H. Pehamberger, K. Wolff, P. Palese, and T. Muster (2000)
J. Virol. 74, 6203-6206
   Abstract »    Full Text »
Intergeneric poliovirus recombinants for the treatment of malignant glioma.
M. Gromeier, S. Lachmann, M. R. Rosenfeld, P. H. Gutin, and E. Wimmer (2000)
PNAS 97, 6803-6808
   Abstract »    Full Text »    PDF »
Oncolysis of Diffuse Hepatocellular Carcinoma by Intravascular Administration of a Replication-competent, Genetically Engineered Herpesvirus.
T. M. Pawlik, H. Nakamura, S. S. Yoon, J. T. Mullen, S. Chandrasekhar, E. A. Chiocca, and K. K. Tanabe (2000)
Cancer Res. 60, 2790-2795
   Abstract »    Full Text »    PDF »
Complement Depletion Facilitates the Infection of Multiple Brain Tumors by an Intravascular, Replication-Conditional Herpes Simplex Virus Mutant.
K. Ikeda, H. Wakimoto, T. Ichikawa, S. Jhung, F. H. Hochberg, D. N. Louis, and E. A. Chiocca (2000)
J. Virol. 74, 4765-4775
   Abstract »    Full Text »
Ras Activation in Normal White Blood Cells and Childhood Acute Lymphoblastic Leukemia.
F. C. von Lintig, I. Huvar, P. Law, M. B. Diccianni, A. L. Yu, and G. R. Boss (2000)
Clin. Cancer Res. 6, 1804-1810
   Abstract »    Full Text »    PDF »
An oncolytic herpes simplex virus type 1 selectively destroys diffuse liver metastases from colon carcinoma.
S. S. YOON, H. NAKAMURA, N. M. CARROLL, B. P. BODE, E. A. CHIOCCA, and K. K. TANABE (2000)
FASEB J 14, 301-311
   Abstract »    Full Text »
Recent Developments in the Virus Therapy of Cancer.
T. A. Steele (2000)
Experimental Biology and Medicine 223, 118-127
   Abstract »    Full Text »
B-myb Promoter Retargeting of Herpes Simplex Virus gamma 34.5 Gene-Mediated Virulence toward Tumor and Cycling Cells.
R. Y. Chung, Y. Saeki, and E. A. Chiocca (1999)
J. Virol. 73, 7556-7564
   Abstract »    Full Text »
Multimodal Cancer Treatment Mediated by a Replicating Oncolytic Virus That Delivers the Oxazaphosphorine/Rat Cytochrome P450 2B1 and Ganciclovir/Herpes Simplex Virus Thymidine Kinase Gene Therapies.
M. Aghi, T. C. Chou, K. Suling, X. O. Breakefield, and E. A. Chiocca (1999)
Cancer Res. 59, 3861-3865
   Abstract »    Full Text »    PDF »
When Two Is Better Than One: Thoughts on Three Decades of Interaction between Virology and the Journal of Virology.
(1999)
J. Virol. 73, 3520-3523
   Full Text »
Another Advance in Tumor-Killing Viruses.
(1999)
Journal Watch Dermatology 1999, 18
   Full Text »
Another Advance in Tumor-Killing Viruses.
(1998)
Journal Watch (General) 1998, 2
   Full Text »
gamma -Phosphate Protonation and pH-dependent Unfolding of the Ras{middle dot}GTP{middle dot}Mg2+ Complex. A VIBRATIONAL SPECTROSCOPY STUDY.
H. Cheng, S. Sukal, R. Callender, and T. S. Leyh (2001)
J. Biol. Chem. 276, 9931-9935
   Abstract »    Full Text »    PDF »


To Advertise     Find Products

Science. ISSN 0036-8075 (print), 1095-9203 (online)